Company Name Taligen Therapeutics
Mailing Address 12635 East Montview Blvd Aurora, CO 80045
Company Description Taligen’s lead technology is directed at inhibiting factor B, an essential component in the amplification of complement activation. Inhibition of factor B down-regulates complement activation, thereby dampening the inflammatory response. Taligen’s second technology is able to target complement inhibitors specifically to sites where excessive complement activation is occurring, thereby controlling inflammation at a specific tissue site.